Premium
IC‐P‐141: AZD4694: Fluorinated Positron Emission Tomography (PET) radioligand for detection of β‐amyloid deposits
Author(s) -
SundgrenAndersson Anna K.,
Svensson Samuel P.S.,
Swahn BrittMarie,
Juréus Anders,
Sandell Johan,
Johnson Allan E.,
Jeppsson Fredrik,
Neelissen Jan A.M.,
Halldin Christer,
Johnström Peter,
Schou Magnus,
Cselényi Zsolts,
Farde Lars
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.05.113
Subject(s) - radioligand , ex vivo , pittsburgh compound b , positron emission tomography , amyloid (mycology) , in vivo , human brain , chemistry , congo red , pathology , white matter , in vitro , alzheimer's disease , medicine , nuclear medicine , biochemistry , neuroscience , biology , magnetic resonance imaging , disease , microbiology and biotechnology , organic chemistry , adsorption , radiology
IC-P-141 AZD4694: FLUORINATED POSITRON EMISSION TOMOGRAPHY (PET) RADIOLIGAND FOR DETECTION OF b-AMYLOID DEPOSITS Anna K. Sundgren-Andersson, Samuel P. S. Svensson, BrittMarie Swahn, Anders Juréus, Johan Sandell, Allan E. Johnson, Fredrik Jeppsson, Jan A. M. Neelissen, Christer Halldin, Peter Johnström, Magnus Schou, Zsolts Cselényi, Lars Farde, AstraZeneca, Sodertalje, Sweden; Dept. of Clinical Neuroscience, Karolinska Institutet, Sweden. Contact e-mail: Samuel.Svensson@astrazeneca.com